GLOBAL PROSTATE CANCER OUTCOMES REGISTRY PCOR AND THE DELPHI PROJECT
|
|
- Bernard Cannon
- 6 years ago
- Views:
Transcription
1 GLOBAL PROSTATE CANCER OUTCOMES REGISTRY PCOR AND THE DELPHI PROJECT
2 Objectives Provide an overview of the registry/timeline Describe the dataset development Discuss the Delphi consensus quality indicator project Outline the next steps
3 PCOR- VIC PCOR- ANZ TRUENTH GLOBAL PCOR
4 PCOR-Vic Prostate Cancer Outcome Registry-Victoria (PCOR-VIC) Established 2009 to test feasibility of clinician-led registry to monitor quality of care 6 sites Extended to two regional areas with additional funding Currently captures 75% of cases in Victoria
5 PCOR-Vic
6 PCOR-Vic Hospital volume Positive margins Documented ct AS for low-risk disease High-risk disease having Rx Risk adjusted CaP-specific survival and recurrence PRO-sexual, bowel and urinary bother and function In-hospital death from major complications Time from biopsy to treatment for men with pt2 disease
7 PCOR-Vic % of men met selected QIs 100% 80% 60% 40% 20% 0% Trend in Quality Care Improvement in Victoria Year % positive surgical margins for organ-confined pathological T2 disease % of men with low-risk group who underwent prostate cancer treatment
8 Temporal trend - stage at diagnosis 100% 80% High risk Very high risk/ metastatic V high/ mets 6.1% to 10.5% (2011) (2016) 60% P< % 20% Low risk Intermediate Low risk 30% to 20% (2011) (2016) 0% 2010 (n=2428) 2011 (n=2422) 2012 (n=2496) 2013 (n=2186) 2014 (n=2147) 2015 (n=2221) To 1/7/2016 (n=1033) Low Intermediate High Very high/mets
9 Temporal trend - Method of diagnosis 100% 80% TURP Clinical/other Transperineal 60% 40% TRUS P< % 0% 2010 (n=2428) 2011 (n=2422) 2012 (n=2496) 2013 (n=2186) 2014 (n=2147) 2015 (n=2221) To 1/7/2016 (n=1033)
10 Temporal trendlow risk disease management 100% 80% AS/WW P< % 40% EBRT BRACHY AS/WW 52% to 75% (2011) (2016) 20% SURGERY Surg 35% to 20% (2011) (2016) 0% 2010 (n=640) 2011 (n=710) 2012 (n=660) 2013 (n=529) 2014 (n=454) 2015 (n=468) To 1/7/2016 (n=208) Surg EBRT Brachy AS/WW
11 Temporal trendintermediate risk disease management 100% 80% EBRT EBRT 16% to 11% (2011) (2016) 60% AS/WW AS/WW 13% to 18% (2011) (2016) 40% P< % SURGERY 0% 2010 (n=1021) 2011 (n=1016) 2012 (n=1085) 2013 (n=980) 2014 (n=961) 2015 (n=984) Surg AS/WW EBRT Surg+EBRT Brachy Other To 1/7/2016 (n=463)
12 Temporal trend High risk disease management (n=3245) 100% 80% ADT AS/WW ADT 15% to 8% (2011) (2016) 60% EBRT P< % 20% SURGERY Surg 40% to 51% (2011) (2016) 0% 2010 (n=520) 2011 (n=511) 2012 (n=526) 2013 (n=459) 2014 (n=483) 2015 (n=467) To 1/7/2016 (n=220) Surg EBRT Surg+EBRT ADT AS/WW
13 Very high risk/ metastatic disease (n=1153) 100% OTHER 80% ADT 60% 40% CHEMO Chemo 3% to 14% (2011) (2016) 20% EBRT 0% 2010 (n=174) 2011 (n=145) 2012 (n=171) 2013 (n=157) 2014 (n=178) SURGERY 2015 (n=215) To 1/7/2016 (n=104) Surg EBRT Chemo ADT Other
14 PCOR-ANZ Prostate Cancer Outcome Registry-Aust and NZ Progressively rolled out National indicators developed through Delphi panel
15 PCOR-ANZ Data Cancer registries Mandatory hospital and pathology notifications Demographic details Diagnosing clinician/hospital Hospital databases Procedures (electronically where possible) Pathology (PSA levels)/ histopathology Consulting rooms Treatment PSA level Patients Treatment confirmation PROMs Comorbidities (no ICD complications)
16 TrueNTH Global Prostate Cancer Registry Prostate Cancer Outcome Registry-Global registry
17 TrueNTH Global Prostate Cancer Registry Largest international prostate cancer cohort study to date. It provides the ability to make a large contribution to our knowledge of how prostate cancer can best be managed to provide the best possible outcomes for men, their partners and their families.
18 TrueNTH Global Prostate Cancer Registry 2012: Movember funded first registry effort- PCOR-ANZ 2013: ICHOM face-to-face meeting Harvard Uni, Boston 2015: (July) PCO-CRV project EOI released for global coordination centre 2016: (May) PCO-CRV project protocol v1 for comment 2017: (Jan) PCO-CRV project commencement date : Movember funded IPCOR- Irish Prostate Cancer initiative 2013: ICHOM localised prostate cancer minimum dataset released 2015: (Dec) PCO-CRV kick off meeting in LA. PCC/DCC led 2016: (Dec) PCO-CRV protocol released for HREC authorisation 2017: (July) PCO-CRV project data managers meeting
19 TrueNTH Global Prostate Cancer Registry 2012: Movember funded first registry effort- PCOR-ANZ 2013: ICHOM face-to-face meeting Harvard Uni, Boston 2015: (July) PCO-CRV project EOI released 2016: (May) PCO-CRV project protocol v1 for comment 2017: (Jan) PCO-CRV project commencement date : Movember funded IPCOR- Irish Prostate Cancer initiative 2013: ICHOM localised prostate cancer minimum dataset released 2015: (Dec) PCO-CRV kick off meeting in LA. PCC/DCC led 2016: (Dec) PCO-CRV protocol released for HREC authorisation 2017: (July) PCO-CRV project data managers meeting
20 ICHOM Goals Develop consensus standardised minimum dataset Facilitate comparative effectiveness research and foster value-based healthcare, designed to engender competition between high-quality entities to achieve better outcomes for patients and simultaneously optimize cost of this care. Facilitate international collaborations to combine data, allow comparisons, insight into high value and high quality features of care, and action to adopt these more widely Mechanism to do this was not described
21 ICHOM Goals Develop consensus standardised minimum dataset Facilitate comparative effectiveness research and foster value-based healthcare, designed to engender competition between high-quality entities to achieve better outcomes for patients and simultaneously optimize cost of this care. Facilitate international collaborations to combine data, allow comparisons, insight into high value and high quality features of care, and action to adopt these more widely Mechanism to do this was not described
22 Study schema
23 ICHOM Goals Develop consensus standardised minimum dataset Facilitate comparative effectiveness research and foster value-based healthcare, designed to engender competition between high-quality entities to achieve better outcomes for patients and simultaneously optimize cost of this care. Facilitate international collaborations to combine data, allow comparisons, insight into high value and high quality features of care, and action to adopt these more widely Mechanism to do this was not described
24 The theory of positive deviance Identify organisations consistently achieving high performance in area of interest Study this organisation using qualitative methods to generate hypotheses about why this is occurring Test hypotheses in larger representative sample Disseminate evidence about newly characterised best practice
25 Timeline 2012: Movember funded first registry effort- PCOR-ANZ 2013: ICHOM face-to-face meeting Harvard Uni, Boston 2015: (July) PCO-CRV project EOI released 2016: (May) PCO-CRV project protocol with proposed dataset 2017: (Jan) PCO-CRV project commencement date : Movember funded IPCOR- Irish Prostate Cancer initiative 2013: ICHOM localised prostate cancer minimum dataset released 2015: (Dec) PCO-CRV kick off meeting in LA. PCC/DCC 2016: (Dec) PCO-CRV protocol released for HREC authorisation 2017: (July) PCO-CRV project data managers meeting
26 Task 1: Identify participating sites and coordination centre EOI released mid-2015 for Participating Sites and Data Coordination Centre Participating Sites contribute to data governance, dataset development and evolution, analysis, dissemination of identified best practice, and monitoring change Data Coordination Centre: hosts the clinical quality registry providing high security, highly reliable, flexible controlled storage and data manipulation services Coordinates activities of the Participating Sites. Conducting principal data analyses under the guidance of the project Steering Committee
27 DCC and PCC appointed PCC DCC
28 Task 2: is ICHOM data collection feasible? Data discovery project-dcc
29 Task 2: is ICHOM data collection feasible?
30 Task 2: is ICHOM data collection feasible?
31 Task 2: is ICHOM data collection feasible? Not straight away.. Concept of Tier 1 (T1) and Tier 2 (T2) introduced. By the PCO-CRV Executive Committee
32 G-PCOR Governance structure Global Prostate Cancer Outcomes Steering Committee Joint DCC and PCC* (Monash and UCLA) Leadership team Executive Committee PCO-CRV Project Steering Committee Czech New Australia Austria Canada Germany Ireland Italy Netherlands Spain Republic Zealand Switzerland United Kingdom USA * DCC=Global Data Coordination Centre PCC= Global Project coordination Centre
33 G-PCOR study sites
34 G-PCOR governance DCC we are all about the data and the database where it is stored We are your contact for: Any queries about data export, transfer and load Any issues with the upload Any issues with data formatting Any technical issues relating to the reports Getting access to your research data through Safe Haven PCC we are all about the project management We are your contact for: Any issues with recruitment Any requests to do with research project requests Discussion on quality improvement activities Distribution and shared of your learnings Anything to do with meetings
35 MODIFIED DELPHI PROCESS TO DEVELOP GLOBAL QUALITY INDICATORS
36 Modified Delphi panel Select a reasonable number of indicators that can measure the quality of prostate cancer management worldwide. Refine and reduce the number of quality-of-care indicators that were derived from the clinical guideline literature review. Disclaimer: We acknowledge that there are many important indicators that have not been considered in this panel discussion. Many indicators had to be excluded after the literature review due to the limitations of the PCOR-CRV dataset.
37 What is a Delphi panel? Delphi A process for determining consensus on something It is iterative (one round builds on the next) 3 rounds Begins with an open ended questionnaire to solicit information about a subject Often a large group participate **The modified Delphi technique is similar to the full Delphi in terms of procedure (i.e., a series of rounds with selected experts) and intent (i.e., to predict future events and to arrive at consensus). Modified Delphi Not part of the original Delphi process It is an iterative process with 3 rounds including a face-to-face meeting Begins with a set of carefully selected items for discussion Only 9-14 people participate Allows for expert interaction to provide clarification on matters and to present arguments in order to justify their point of view Studies show it is can be superior to Delphi 3,4
38 The Delphi panel
39 The Delphi process 1. Literature review 2. Feasibility with existing data 3. Online survey 1 4. Analysis of online survey 5. Face to face panel meeting 6. Online survey 2
40 The Delphi process 1. Literature review 2. Feasibility with existing data 3. Online survey 1 4. Analysis of online survey 5. Face to face panel meeting 6. Online survey 2
41 Guidelines Ref Pub FULL REFERENCE Alberta HS 2015 Alberta Health Services Clinical Practice Guidelines for Prostate Cancer Andrology AUS 2010 Andrology Australia - Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Cancer (Australia) AUA 2013 American Urological Association - Radiotherapy after Prostatectomy (United States of America) AUA Cyrosurgery 2008 American Urological Association Best Practice Policy Statement on Cyrosurgery for the Treatment of Localised Prostate Cancer BAUS 2013 British Association of Urological Surgeons - Section of Oncology (United Kingdom) Cancer Care Ontario 2014 Cancer Care Ontario 2014 Active Surveillance for the Management of Localized Prostate Cancer (Canada) Cancer Council 2016 Cancer Council - Prostate Cancer Clinical Guidelines (Australia) EAU ED 2015 European Association of Urology - Guidelines on Male Sexual Dysfunction EAU 2017 European Association of Urology - Guidelines on Prostate Cancer (Netherlands)
42 Guidelines Ref Year Guideline/ Reference EAU 2017 European Association of Urology - Guidelines on Prostate Cancer (Netherlands) ESMO 2015 KCE 2014 European Society for Medical Oncology - Cancer of the Prostate: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up (Switzerland) Belgian Health Care Knowledge Centre - National Practice Guideline on the Treatment of Localized Prostate Cancer (Belgium) NCI 2016 National Cancer Institute - Prostate Cancer Treatment (United States of America) NCCN 2017 National Comprehensive Cancer Network - Clinical Practice Guidelines in Oncology: Prostate Cancer (United States of America) NCCP 2015 National Cancer Control Programme - Diagnosis, Staging and Treatment of Patients with Prostate Cancer (Ireland) NCCS 2013 National Cancer Centre Singapore - Guidelines on Management of Prostate Cancer (Singapore) NICE 2016 National Institute for Health and Care Excellence - Prostate Cancer: Diagnosis and Management (United Kingdom) NZ PCT 2013 Prostate Cancer Taskforce (New Zealand) VIC-OCP 2015 Optimal Care Pathway for Men with Prostate Cancer (Victoria, Australia)
43 Articles Ref (et al) Year FULL REFERENCE Ahmadi 2014 Androgen Deprivation Therapy for Prostate Cancer Patient Relat Outcome Meas., 5:63-70 Ahmed 2014 Chin 2015 Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus X, Radiation Oncology, 9:171 Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation or Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical trial, European Urology, 70: Loeb 2013 Systematic review of complications of prostate biopsy Eur.Urol., 64 (6), pp Nag 2016 Development of Indicators to Assess Quality of Care for Prostate Cancer. Eur Urol Focus Punnen 2015 Ramsay 2015 Long-Term Health-Related Quality of Life after Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry, European Urology, 68(4): Ablative therapy for People with Localized Prostate Cancer: A Systematic Review and Economic Evaluation - Chapter 4: The Comparative Effectiveness of Cryotherapy, Health Technology Assessment, No Resnick 2013 Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer, N Engl J Med Jan 31;368(5): Robinson 2009 A Randomized Trial of External Beam Radiotherapy versus Cryoblation in Patients with Localized Prostate Cancer Quality of Life Outcomes, Cancer, 115 (20) Wegner 2014 Laser Ablation as Focal Therapy for Prostate Cancer, Curr Opin Uro, 24(3): Yap 2016 The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials, European Urology, 69(5):
44 The Delphi process 1. Literature review 2. Feasibility with existing data 3. Online survey 1 4. Analysis of online survey 5. Face to face panel meeting 6. Online survey 2
45 Which indicators to include 1. Those where there is a high level of agreement among the panel that it is a good indicator = Median score 2. Those where there is little disagreement (dispersion) among the panel that it is a good indicator = Disagreement Index (DI)
46 The Delphi process Median score 7-9 and no disagreement (DI<1) Any disagreement regardless of median score (DI 1) Median score 1-6 and no disagreement
47 The Delphi process Panellist ID #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 Rating given (from 1-9) Median: 5 Lower IPR: 10 th percentile = 2 Upper IPR: 90 th percentile = 8 IPR: 8-2 = 6 IPRCP: (2+8) / 2 = 5 Asymmetry index: 5-5 = 0 IPRAS: (1.5 x 0) = 2.35 Disagreement Index (DI): 6 / 2.35 = 2.55
48 The Delphi process Panellist ID #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 Rating given (from 1-9) Median: 8 Lower IPR: 10 th percentile = 1 Upper IPR: 90 th percentile = 9 IPR: 9-1 = 8 IPRCP: (1+9) / 2 = 5 Asymmetry index: 5-5 = 0 IPRAS: (1.5 x 0) = 2.35 Disagreement Index (DI): 8 / 2.35 = 3.40
49 The Delphi process Panellist ID #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 Rating given (from 1-9) Median: 5 Lower IPR: 10 th percentile = 4 Upper IPR: 90 th percentile = 6 IPR: 6-4 = 2 IPRCP: (4+6) / 2 = 5 Asymmetry index: 5-5 = 0 IPRAS: (1.5 x 0) = 2.35 Disagreement Index (DI): 2 / 2.35 = 0.85
50 The Delphi process 1. Literature review 2. Feasibility with existing data 3. Online survey 1 4. Analysis of online survey 5. Face to face meeting 6. Online survey 2 This means that the Median panel score (scale 1-9) was 9 and the Disagreement Index was 0.37
51 Results from round 1 Arghhh!!!!!
52 The Delphi process 1. Literature review 2. Feasibility with existing data 3. Online survey 1 4. Analysis of online survey 5. Face to face panel meeting 6. Online survey 2
53 Vancouver
54 The Delphi process Face to face meeting Rated importance AND feasibility (scale 1-9)
55 The Delphi process
56 Quality indicators # Indicator Diag Initial investigations of a male with PCa include measurement of PSA level Diag T category/stage (DRE or MRI) is documented prior to treatment for localised PCa Diag In men with high risk localised PCa, nodal staging using CT, MRI or PET/CT is performed Diag In men with high risk localised PCa, perform metastatic screening using a CT/MRI and a bone scan Diag In men with intermediate risk localised PCa, a bone scan is not conducted
57 Quality indicators # Indicator Diag Diag Primary Rx Primary Rx Primary Rx Primary Rx In men with low risk PCa, a bone scan is not conducted In men with low risk localised PCa, a CT is not conducted Men with high risk localised PCa receive active treatment Men with high risk localised PCa do not receive AS PSA is taken within 3 months post RP For pn0 men undergoing RP, adjuvant ADT is not given
58 Quality indicators # Indicator Men with localised PCa who are undergoing radical EBRT receive a Primary Rx Primary Rx Primary Rx Primary Rx Salvage Rx Outcome minimum dose of 74Gy at standard fractionation or the equivalent of hypofractionation to the prostate PSA level is taken within 12 months post RT Men with high risk localised PCa do not receive brachytherapy alone PSA level is taken within 6 months post focal therapy Men who have salvage RT post RP receive a salvage RT dose 66 Gy at standard fractionation or the equivalent hypo-fractionated dose EPIC-26 is completed 12 months post diagnosis for men on AS and 12 months post active treatment for men receiving active treatment
59 Quality indicators # Indicator Outcome Outcome Outcome Outcome Outcome Outcome EPIC-26 is completed at baseline EORTC QLQ-PR25 is completed 12 months post diagnosis for men on AS and 12 months post active treatment for men receiving active treatment Utilisation of Sexual Medication/Devices is completed 12 months post diagnosis for men on AS and 12 months post active treatment for men receiving active treatment EORTC QLQ-PR25 is completed at baseline Utilisation of Sexual Medication/Devices is completed at baseline Death within 30 days of RP
60 Quality indicators # Indicator Outcome Outcome Men with low risk PCa who had a positive margin post-rp Men with pt2 disease who had a positive margin post-rp Outcome Men with pt3 disease who had a positive margin post-rp Outcome Biochemical recurrence at 1 year post RP Outcome Radical or systemic treatment at 18 months post focal-gland or whole-gland ablation therapy
61 Next steps 1. Publish findings 2. Build the reports 3. Test and refine the indicators 4. Develop reports 5. Distribute reports to LDCs 6. LDCs will distribute reports to participating sites
62 Building the reports
63 Acknowledgement PCO-CRV Monash/Movember team Fanny Sampurno Jeremy Millar Jia Zheng Ellie James Ashwini Kannon Harvey Goh PCO-CRV UCLA team Sarah Connor Delphi panel Mark Litwin Emily Pearman TrueNTH Steering Committee Contributors to the registry PCOR-Vic and ANZ team Melanie Evans Gabriella Tikellis Data collector and follow up team
64 Acknowledgement Funding bodies Thank you PCOR-Vic Steering Committee Contributing clinicians and hospitals Participating men PCOR-Vic data collectors and researchers Endorsing groups
65 Questions?
Prostate Cancer Registry: an update
Prostate Cancer Registry: an update Sue Evans on behalf of the PCR Steering Committee Registry Special Interest Group 10 August 2012 Acknowledgements PCR Project coordinators Julie Wood (metro) Joanne
More informationSurvival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum
7/8/20 7/8/20 Using PROMS to better understand prostate cancer outcomes: The NSW Prostate Cancer Care and Outcomes Study David Smith Research Fellow Cancer Research Division Monash Uni, 26 th June 20 Survival
More informationDate Modified: May 29, Clinical Quality Measures for PQRS
Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3
More informationDate Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationMeasuring the value of healthcare activities. Susan Rollason, Director of Finance and Strategy
Measuring the value of healthcare activities Susan Rollason, Director of Finance and Strategy Items covered What are we doing and why? What have we done so far? What challenges have we faced? What are
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationNational Prostate Cancer Audit. Bill Cross June 2015
National Prostate Cancer Audit Bill Cross June 2015 National Prostate Cancer Audit aim of assessing the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales National
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationEffective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18
PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationAustralian Organisation Launches Large International Clinical Trials in Prostate Cancer
Australian Organisation Launches Large International Clinical Trials in Prostate Cancer Media Release Sydney 8 April, 2014: The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials
More informationINFORMED DECISION MAKING IN THE MANAGEMENT OF LOCALISED PROSTATE CANCER A POSITION STATEMENT ABOUT THIS POSITION STATEMENT DEVELOPMENT
The Royal Australian and New Zealand College of Radiologists The Faculty of Radiation Oncology INFORMED DECISION MAKING IN THE MANAGEMENT OF LOCALISED PROSTATE CANCER A PATIENT-FOCUSED PERSPECTIVE A POSITION
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More information10th anniversary of 1st validated CaPspecific
Quality of Life after Treatment of Localised Prostate Cancer Dr Jeremy Grummet Clinical Uro-Oncology Fellow May 28, 2008 1 Why? This is important May be viewed as soft science Until we know which treatment
More informationTechnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546
Padeliporfin for untreated localised prostate cancer Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationProstate cancer: intervention comparisons
National Institute for Health and Care Excellence Guideline version (Draft) Prostate cancer: intervention comparisons [G] Evidence reviews for active surveillance, radical prostatectomy or radical radiotherapy
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationTable 1 Standards and items to set up a PCU: general requirements and critical mass
Table 1 Standards and items to set up a PCU: general requirements and critical mass General requirements and European Prostate Cancer Units are structures managing sufficient volumes of patients with on-site
More informationCan men on AS be treated with testosterone?
Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationDoes RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationGuideline Prostate cancer: diagnosis and management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Prostate cancer: diagnosis and management (update) Draft for consultation, December 0 This guideline covers diagnosing and managing prostate
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of focal therapy using high-intensity focused ultrasound for localised prostate
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationCORPORATE PRESENTATION OCTOBER 2017
MRgFUS Uterine Fibroids Incision-free Surgery Real-Time MR Guided Ultrasound Therapies Prostate Disease CORPORATE PRESENTATION OCTOBER 2017 2017 PROFOUND MEDICAL CORP. TSXV: PRN OTCQX: PRFMF FORWARD-LOOKING
More informationHow to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationCORPORATE PRESENTATION OCTOBER 2017
MRgFUS Uterine Fibroids Incision-free Surgery Real-Time MR Guided Ultrasound Therapies Prostate Disease CORPORATE PRESENTATION OCTOBER 2017 2017 PROFOUND MEDICAL CORP. TSXV: PRN OTCQX: PRFMF FORWARD-LOOKING
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationBringing prostate cancer education to regional and rural Australian communities
Bringing prostate cancer education to regional and rural Australian communities Julie Sykes 1, Lisa Fodero 2, Nick Brook 3, Rachel Jenkin 4 1 Prostate Cancer Foundation of Australia; 2 Health Consult;
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationIN RADIOTERAPIA BEST PAPERS. Direttore Unità Operativa Complessa Radioterapia Oncologica
IN RADIOTERAPIA BEST PAPERS 2014 FILIPPO ALONGI Direttore Unità Operativa Complessa Radioterapia Oncologica PROSTATE RT: WHERE WE ARE GOING? RT has evolved from radium(1911) to high Technology and high
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationHigh Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera
High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationPercentage of patients who underwent endoscopic procedures following SWL
Non-QPP Measures Measure ID Measure Title Definition Type Domain 1 AQUA12 Benign Prostate Hyperplasia: IPSS improvement after diagnosis Percentage of patients with NEW diagnosis of clinically significant
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationFirst Year Annual Report Organisation of Services and Analysis of Existing Clinical Data
First Year Annual Report Organisation of Services and Analysis of Existing Clinical Data 1 NPCA Annual Report 2014 National Prostate Cancer Audit First Year Annual Report Organisation of Services and Analysis
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationQuality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care
Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationHDR vs. LDR Is One Better Than The Other?
HDR vs. LDR Is One Better Than The Other? Daniel Fernandez, MD, PhD 11/3/2017 New Frontiers in Urologic Oncology Learning Objectives Indications for prostate brachytherapy Identify pros/cons of HDR vs
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationIntroduction. American Society of Clinical Oncology All rights reserved.
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement This is an endorsement
More informationLinac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery
Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico
More informationINTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)
INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT NECN N Tees & Hartlepool North Tees And Hartlepool Date Self Assessment Completed 23rd July 2009 Date of IV Review 19th June 2009
More informationScreening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014
Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014 Canadian Task Force on Preventive Health Care October 2014 Putting Prevention into Practice Canadian Task
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationManaging Prostate Cancer in General Practice
Managing Prostate Cancer in General Practice Tuesday 18 th September 2018 Presenters: Prof Jon Emery Assoc Prof Declan Murphy The education has been developed in partnership with Cancer Council Victoria,
More informationExternal Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More information